Teclistamab

TECVAYLI®

Overview

Teclistamab is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.

SparkCures ID 279
Developed By Johnson & Johnson
Brand Name Tecvayli®
Generic Name Teclistamab
Additional Names JNJ-64007957
Treatment Classifications
Treatment Targets
Tags

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Verified
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
MAJESTEC-7
View Trial
Verified
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investi...
MONUMENTAL-6
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alo...
MAJESTEC-4
View Trial
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients...
MMULTI-IMMUNE HR
View Trial
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
IMMUNO-PRISM
View Trial
Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple...
LIMITEC
View Trial
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
TECLISTAMAB
View Trial
Teclistamab or Talquetamab in Combination With Daratumumab SC for High-Risk Smoldering Myeloma: A Clinical ...
REVIVE
View Trial
MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
MASTER-2
View Trial
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
HORIZON ADAPTIVE PLATFORM
View Trial
Improving MRD Negativity Rates in Newly Diagnosed Multiple Myeloma Patients: a Response-adaptive Approach o...
ROTATE
View Trial
A Phase II Safety and Efficacy Study of Selinexor in Combination With Bispecific Antibody in Patients With ...
SELINEXOR + BISPECIFIC ANTIBODY
View Trial
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
TECVAYLI
View Trial
ALTITUDE - ALTernating Induction Therapies to Achieve Undetectable Disease Endpoints: A Phase 1/2 Alternati...
ALTITUDE
View Trial
Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
TECLISTAMAB AND MEZIGDOMIDE
View Trial
Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Verified
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
MAJESTEC-7
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alo...
MAJESTEC-4
View Trial
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients...
MMULTI-IMMUNE HR
View Trial
MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
MASTER-2
View Trial
ALTITUDE - ALTernating Induction Therapies to Achieve Undetectable Disease Endpoints: A Phase 1/2 Alternati...
ALTITUDE
View Trial
Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investi...
MONUMENTAL-6
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple...
LIMITEC
View Trial
Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
TECLISTAMAB AND MEZIGDOMIDE
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investi...
MONUMENTAL-6
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple...
LIMITEC
View Trial
A Phase II Safety and Efficacy Study of Selinexor in Combination With Bispecific Antibody in Patients With ...
SELINEXOR + BISPECIFIC ANTIBODY
View Trial
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
TECVAYLI
View Trial
Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
TECLISTAMAB AND MEZIGDOMIDE
View Trial
Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients...
MMULTI-IMMUNE HR
View Trial
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
IMMUNO-PRISM
View Trial
Teclistamab or Talquetamab in Combination With Daratumumab SC for High-Risk Smoldering Myeloma: A Clinical ...
REVIVE
View Trial
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Teclistamab Triplets Show ‘Unprecedented’ Efficacy as Myeloma Induction Therapy

September 22, 2025

Forty-nine patients aged 18-70 years received teclistamab combined with either daratumumab plus lenalidomide (Arm A/A1; n=10/20) or daratumumab plus bortezomib (Arm B; n=19) as induction therapy. Teclistamab was administered in six 28-day cycles, including two step-up doses in cycle 1. Dexamethasone maintenance (20 mg) was also added in the first four cycles in Arm A and the first two cycles in Arms A1/B. The median duration of treatment was 7.0 months, and two patients discontinued all treatments.

Thirty-two (65.3%) patients experienced grade 1-2 cytokine release syndrome. There were no immune effector cell-associated neurotoxicity syndrome events or TEAEs leading to full study treatment discontinuation or death.

All (100%) patients achieved an overall response, and all 46 (100%) MRD-evaluable patients achieved MRD negativity at both 10−5 and 10−6 sensitivity after cycle 6.

Read More

Resources

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smolderi...

December 09, 2023

Read More
FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

October 25, 2022

Read More
Teclistamab Earns Breakthrough Therapy Designation for R/R Multiple Myeloma

June 02, 2021

Read More